IP Library Patent Application 11751806
Patent Application
App. No. 11/751,806

OPHTHALMIC COMPOSITION CONTAINING A POLYOL-ACID COPOLYMER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/751,806
Abstract

An ophthalmic composition comprising a copolymer and one or more cationic antimicrobial components. The copolymer comprises monomeric units of one or more polymerizable alcohols or polymerizable polyols, and monomeric units of one or more polymerizable carboxylic acids. Also, the composition has an osmolality from 200 mOsmol/kg to 400 mOsmol/kg.

Claims (22)

1 . An ophthalmic composition comprising:

a copolymer comprising monomeric units of one or more polymerizable alcohols or polymerizable polyols, and monomeric units of one or more polymerizable carboxylic acids; and

one or more antimicrobial components, wherein the composition has an osmolality from 200 mOsmol/kg to 400 mOsmol/kg.

2 . The composition of claim 1 wherein the copolymer has a mole ratio of monomeric units of the polymerizable alcohol or polyol to the monomeric units of the polymerizable carboxylic acid of from 2 to 20.

3 . The composition of claim 1 wherein the polymerizable polyols are selected from the group consisting of erythritol (meth)acrylate, xylitol (meth)acrylate, sorbitol (meth)acrylate, and derivatives thereof.

4 . The composition of claim 1 wherein the polymerizable alcohols are selected from the group consisting of glyceryl (meth)acrylate, 4-vinylcyclohexyl-1,2-epoxide, vinyl alcohol and derivatives thereof.

5 . The composition of claim 1 wherein the monomeric units of polymerizable carboxylic acids are selected from the group consisting of (meth)acrylic acid, vinyl derivatives of carboxyalkyl cellulose, vinyl glutamic acid, vinyl aspartic acid and derivatives thereof.

6 . The composition of claim 1 wherein the antimicrobial component is a cationic antimicrobial component selected from the group consisting of cetylpyridinium chloride, α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride, myristamidopropyl dimethylamine, benzalkonium halides, alexidine and salts thereof and hexamethylene biguanides and salts thereof and their polymers.

7 . The composition of claim 6 wherein the cationic antimicrobial component is selected from the group consisting of PHMB or PHMB-CG, which is present from 0.01 ppm to 3 ppm, α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl) ammonium chloride, which is present from 1 ppm to 100 ppm, and any mixture thereof.

8 . The composition of claim 1 further comprising dexpanthenol, sorbitol or any mixture thereof.

9 . The composition of claim 1 further comprising 2-amino-2-methyl-1,3-propanediol, and glycolic acid, aspartic acid or a mixture thereof, wherein a molar ratio of the total glycolic acid, aspartic acid or mixture thereof to AMPD is from 1:20 to 1.3:1.

10 . The composition of claim 1 further comprising hyaluronic acid.

11 . The use of the ophthalmic composition of claim 1 in an eye care or a contact lens care product selected from the group consisting of eye drops, contact lens preservative solution, contact lens packaging solution, and contact lens multi-purpose solution.

12 . An ophthalmic composition that includes a copolymer comprising monomeric units of glyceryl (meth)acrylate and monomeric units of (meth)acrylic acid, and one or more cationic antimicrobial components, wherein the composition has an osmolality from 200 mOsmol/kg to 400 mOsmol/kg.

13 . The composition of claim 12 wherein the copolymer has a mole ratio of monomeric units of glyceryl (meth)acrylate and monomeric units of (meth)acrylic acid of from 2 to 12.

14 . The composition of claim 12 wherein the cationic antimicrobial component is selected from the group consisting of cetylpyridinium chloride, α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride, myristamidopropyl dimethylamine, benzalkonium halides, alexidine and salts thereof, hexamethylene biguanides and salts thereof and their polymers, and mixtures thereof.

15 . The composition of claim 12 wherein the cationic antimicrobial component is selected from the group consisting of PHMB or PHMB-CG, which is present from 0.01 ppm to 3 ppm, α-[4-tris(2-hydroxyethyl) ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl) ammonium chloride, which is present from 1 ppm to 100 ppm, and any mixture thereof.

16 . The composition of claim 12 further comprising dexpanthenol, sorbitol or any mixture thereof.

17 . The composition of claim 12 further comprising 2-amino-2-methyl-1,3-propanediol, and glycolic acid, aspartic acid or a mixture thereof, wherein a molar ratio of the total glycolic acid, aspartic acid or mixture thereof to AMPD is from 1:20 to 1.3:1.

18 . The composition of claim 12 further comprising hyaluronic acid.

19 . An ophthalmic composition that includes a copolymer comprising monomeric units of N-vinylpyrrolidone and monomeric units of one or more polymerizable carboxylic acids, and one or more cationic antimicrobial components, wherein the composition has an osmolality from 200 mOsmol/kg to 400 mOsmol/kg.

20 . The composition of claim 19 wherein the copolymer has a mole ratio of monomeric units of the N-vinylpyrrolidone to the monomeric units of the polymerizable carboxylic acid of from 4 to 20.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Nov 16, 2007
From: BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; IOLAB CORPORATION; RHC HOLDINGS, INC.; WP PRISM, INC.
To: CREDIT SUISSE
Reel/Frame 020122/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2007
From: ZHAO, FANG; BARNIAK, VICKI L.; LANG, WEIHONG; MILLARD, KIMERLY; LAI, YU-CHIN
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 019327/0442 →